Cover Image
市場調查報告書

專業蛋白轉換酵素Subtilisin/Kexin9型 (PCSK9) :開發中產品分析

Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis-Regulated Convertase 1 or PCSK9 or EC 3.4.21.) - Pipeline Review, H1 2016

出版商 Global Markets Direct 商品編碼 363582
出版日期 內容資訊 英文 128 Pages
訂單完成後即時交付
價格
Back to Top
專業蛋白轉換酵素Subtilisin/Kexin9型 (PCSK9) :開發中產品分析 Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis-Regulated Convertase 1 or PCSK9 or EC 3.4.21.) - Pipeline Review, H1 2016
出版日期: 2016年06月22日 內容資訊: 英文 128 Pages
簡介

本報告提供專業蛋白轉換酵素Subtilisin/Kexin9型 (PCSK9)的開發情形相關的資訊,各開發階段、藥物標的、作用機制、給藥途徑及各分子類型的分析,開發治療藥的企業概要,最新消息和新聞稿等資訊,為您概述為以下內容。

簡介

  • 調查範圍

專業蛋白轉換酵素Subtilisin/Kexin9型 (PCSK9)的概要

治療藥的開發

專業蛋白轉換酵素Subtilisin/Kexin9型 (PCSK9):開發中的產品 - 各開發階段

專業蛋白轉換酵素Subtilisin/Kexin9型 (PCSK9):開發中的產品 - 各治療範圍

專業蛋白轉換酵素Subtilisin/Kexin9型 (PCSK9):開發中的產品 - 各適應症

專業蛋白轉換酵素Subtilisin/Kexin9型 (PCSK9):開發中產品概況

  • 後期階段的產品
  • 初期階段的產品
  • 開發階段不明的產品

專業蛋白轉換酵素Subtilisin/Kexin9型 (PCSK9):企業開發中的產品

專業蛋白轉換酵素Subtilisin/Kexin9型 (PCSK9):大學/機關開發中的產品

專業蛋白轉換酵素Subtilisin/Kexin9型 (PCSK9):治療藥的評估

  • 各單劑療法/聯合治療產品
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

專業蛋白轉換酵素Subtilisin/Kexin9型 (PCSK9)的治療藥的開發企業

  • Abeome Corporation
  • AFFiRiS AG
  • Alnylam Pharmaceuticals, Inc.
  • Amgen Inc.
  • Betagenon AB
  • BioLingus AG
  • Catabasis Pharmaceuticals, Inc.
  • 第一三共
  • Eli Lilly and Company
  • HitGen LTD
  • 興和
  • Kymab Limited
  • MedImmune, LLC
  • Merck & Co., Inc.
  • Pfizer Inc.
  • Planet Biotechnology Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Serometrix, LLC
  • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
  • Thetis Pharmaceuticals LLC

藥物簡介

專業蛋白轉換酵素Subtilisin/Kexin9型 (PCSK9):暫停中的計劃

專業蛋白轉換酵素Subtilisin/Kexin9型 (PCSK9):開發中止的產品

專業蛋白轉換酵素Subtilisin/Kexin9型 (PCSK9):主要消息與新聞稿

附錄

目錄
Product Code: GMDHC0250TDB

Summary

Global Markets Direct's, 'Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis-Regulated Convertase 1 or PCSK9 or EC 3.4.21.) - Pipeline Review, H1 2016', provides in depth analysis on Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis-Regulated Convertase 1 or PCSK9 or EC 3.4.21.) targeted pipeline therapeutics.

The report provides comprehensive information on the Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis-Regulated Convertase 1 or PCSK9 or EC 3.4.21.), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis-Regulated Convertase 1 or PCSK9 or EC 3.4.21.) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis-Regulated Convertase 1 or PCSK9 or EC 3.4.21.)
  • The report reviews Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis-Regulated Convertase 1 or PCSK9 or EC 3.4.21.) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis-Regulated Convertase 1 or PCSK9 or EC 3.4.21.) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis-Regulated Convertase 1 or PCSK9 or EC 3.4.21.) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis-Regulated Convertase 1 or PCSK9 or EC 3.4.21.) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis-Regulated Convertase 1 or PCSK9 or EC 3.4.21.)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis-Regulated Convertase 1 or PCSK9 or EC 3.4.21.) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis-Regulated Convertase 1 or PCSK9 or EC 3.4.21.) Overview
  • Therapeutics Development
    • Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis-Regulated Convertase 1 or PCSK9 or EC 3.4.21.) - Products under Development by Stage of Development
    • Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis-Regulated Convertase 1 or PCSK9 or EC 3.4.21.) - Products under Development by Therapy Area
    • Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis-Regulated Convertase 1 or PCSK9 or EC 3.4.21.) - Products under Development by Indication
  • Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis-Regulated Convertase 1 or PCSK9 or EC 3.4.21.) - Pipeline Products Glance
    • Late Stage Products
    • Early Stage Products
    • Unknown Stage Products
  • Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis-Regulated Convertase 1 or PCSK9 or EC 3.4.21.) - Products under Development by Companies
  • Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis-Regulated Convertase 1 or PCSK9 or EC 3.4.21.) - Products under Development by Universities/Institutes
  • Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis-Regulated Convertase 1 or PCSK9 or EC 3.4.21.) - Therapeutics Assessment
    • Assessment by Monotherapy/Combination Products
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis-Regulated Convertase 1 or PCSK9 or EC 3.4.21.) - Companies Involved in Therapeutics Development
    • Abeome Corporation
    • AFFiRiS AG
    • Alnylam Pharmaceuticals, Inc.
    • Amgen Inc.
    • Betagenon AB
    • BioLingus AG
    • Catabasis Pharmaceuticals, Inc.
    • Daiichi Sankyo Company, Limited
    • Eli Lilly and Company
    • HitGen LTD
    • Kowa Company, Ltd.
    • Kymab Limited
    • MedImmune, LLC
    • Merck & Co., Inc.
    • Pfizer Inc.
    • Planet Biotechnology Inc.
    • Regeneron Pharmaceuticals, Inc.
    • Serometrix, LLC
    • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
    • Thetis Pharmaceuticals LLC
  • Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis-Regulated Convertase 1 or PCSK9 or EC 3.4.21.) - Drug Profiles
    • (atorvastatin calcium + TP-452) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • alirocumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ALN-PCSsc - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ATH-04 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ATH-06 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Biologics to Target PCSK-9 for Hypercholesterolemia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • bococizumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CAT-2000 Series - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DS-9001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • evolocumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Gene Therapy to Inhibit PCSK9 for Hypercholesterolemia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • K-312 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • KY-1020 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LY-3015014 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MEDI-4166 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibodies to Inhibit PCSK9 for Hypercholesterolemia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibodies to Inhibit PCSK9 for Hypercholesterolemia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody to Inhibit PCSK9 for Hypercholesterolemia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody to Inhibit PCSK9 for Hypercholesterolemia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • O-304 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant Protein to Inhibit PCSK9 for Hypercholesterolemia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit PCSK9 for Hypercholesterolemia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit PCSK9 for Hypercholesterolemia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit PCSK9 for Acute Coronary Syndrome and Atherosclerosis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit PCSK9 for Coronary Artery Disease and Metabolic Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit PCSK9 for Hypercholesterolemia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SX-PCK9 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Synthetic Peptide to Inhibit PCSK9 for Hypercholesterolemia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TP-452 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Vaccine to Target PCSK9 for Hypercholesterolemia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis-Regulated Convertase 1 or PCSK9 or EC 3.4.21.) - Dormant Projects
  • Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis-Regulated Convertase 1 or PCSK9 or EC 3.4.21.) - Discontinued Products
  • Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis-Regulated Convertase 1 or PCSK9 or EC 3.4.21.) - Featured News & Press Releases
    • Jun 02, 2016: The Medicines Company Completes Patient Enrollment for ORION-1 Study of PCSK9si
    • May 24, 2016: New Cholesterol Treatment Now Available for Canadians
    • May 24, 2016: New study results show cholesterol-lowering medication, Repatha (evolocumab), lowers LDL-C when self-administered in at-home setting
    • May 23, 2016: The Results From A One Year Treatment Of Repatha Presented At The Annual Meeting Of The Japan Diabetes Society
    • May 16, 2016: ICON and Pfizer Honoured as Clinical Research Team of the Year at the Clinical and Research Excellence Awards
    • May 11, 2016: Cigna's New Value-Based Contract with Sanofi/Regeneron for Praluent
    • May 11, 2016: Cigna's New Value-Based Contract with Amgen for Repatha
    • May 06, 2016: Innovative cholesterol-lowering treatment, Praluent (alirocumab), approved by NICE for people with raised cholesterol levels who are at significantly high risk of a heart attack or stroke
    • May 06, 2016: NICE Sets Out Draft Recommendations For Repatha (Evolocumab) In Final Appraisal Determination
    • Apr 26, 2016: Bococizumab SPIRE-2 Cardiovascular Outcome Study Fully Enrolled
    • Apr 21, 2016: Amgen Astellas Biopharma And Astellas Introduce Repatha (Evolocumab) For The Treatment Of High Cholesterol
    • Apr 04, 2016: New study results of Repatha (evolocumab) in statin-intolerant patients published in Journal of the American Medical Association
    • Apr 03, 2016: Positive Efficacy And Tolerability Study Of Repatha (evolocumab) In Statin-Intolerant Patients Published In "Journal of the American Medical Association"
    • Apr 01, 2016: Pfizer Announces Positive Topline Results From Second Phase 3 Lipid-Lowering Study Evaluating Bococizumab
    • Mar 23, 2016: Regeneron and Sanofi Announce Positive Topline Results from Phase 3 Praluent (alirocumab) Study in Patients Undergoing LDL Apheresis Therapy
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for, H1 2016
  • Number of Products under Development by Therapy Area, H1 2016
  • Number of Products under Development by Indication, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Comparative Analysis by Unknown Stage Development, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016 (Contd..1)
  • Products under Development by Companies, H1 2016 (Contd..2)
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Products under Investigation by Universities/Institutes, H1 2016
  • Assessment by Monotherapy/Combination Products, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Pipeline by Abeome Corporation, H1 2016
  • Pipeline by AFFiRiS AG, H1 2016
  • Pipeline by Alnylam Pharmaceuticals, Inc., H1 2016
  • Pipeline by Amgen Inc., H1 2016
  • Pipeline by Betagenon AB, H1 2016
  • Pipeline by BioLingus AG, H1 2016
  • Pipeline by Catabasis Pharmaceuticals, Inc., H1 2016
  • Pipeline by Daiichi Sankyo Company, Limited, H1 2016
  • Pipeline by Eli Lilly and Company, H1 2016
  • Pipeline by HitGen LTD, H1 2016
  • Pipeline by Kowa Company, Ltd., H1 2016
  • Pipeline by Kymab Limited, H1 2016
  • Pipeline by MedImmune, LLC, H1 2016
  • Pipeline by Merck & Co., Inc., H1 2016
  • Pipeline by Pfizer Inc., H1 2016
  • Pipeline by Planet Biotechnology Inc., H1 2016
  • Pipeline by Regeneron Pharmaceuticals, Inc., H1 2016
  • Pipeline by Serometrix, LLC, H1 2016
  • Pipeline by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd., H1 2016
  • Pipeline by Thetis Pharmaceuticals LLC, H1 2016
  • Dormant Projects, H1 2016
  • Dormant Projects (Contd..1), H1 2016
  • Discontinued Products, H1 2016

List of Figures

  • Number of Products under Development for, H1 2016
  • Number of Products under Development by Therapy Area, H1 2016
  • Number of Products under Development by Top 10 Indication, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy/Combination Products, H1 2016
  • Number of Products by Stage and Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Molecule Types, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
Back to Top